TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06305104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5μg/ml EEC
Description: 0.1ml ,one time, containing low dose of 2.5μg/ml of active ingredients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5μg/ml EEC
Description: 0.1ml ,one time, containing low dose of 2.5μg/ml of active ingredients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5μg/ml EEC
Description: 0.1ml ,one time, containing low dose of 2.5μg/ml of active ingredients
Study: NCT06433921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-152a
Description: A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-134a
Description: A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-134a
Description: A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals.
Study: NCT06305104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml EEC
Description: 0.1ml, one time, containing high dose 5μg/ml of active ingredients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml EEC
Description: 0.1ml, one time, containing high dose 5μg/ml of active ingredients
Study: NCT05455606

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chart Abstraction
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chart Abstraction
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Physicians access genomic testing education materials

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genomic Profile
Description: Patients undergo genomic testing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genomic Profile
Description: Patients undergo genomic testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor Board Review
Description: Patients undergo genomic tumor board review
Study: NCT05382533

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Menu plans
Description: The study participants in group A and C receive defined personal nutritional counselling every two weeks and they are provided with daily menu plans (isocaloric) with optimized nutrient profiles and chosen study products (plant oils, nuts mixture etc.) over the study period of 10 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Menu plans
Description: The study participants in group A and C receive defined personal nutritional counselling every two weeks and they are provided with daily menu plans (isocaloric) with optimized nutrient profiles and chosen study products (plant oils, nuts mixture etc.) over the study period of 10 weeks.
Study: NCT06433921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals.
Study: NCT05594875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1921
Description: Subject will receive a single dose of SHR-1921 at dose level 1/2/3 on Day of each cycles
Study: NCT06113289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX029-01
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX029-01
Description: Given by PO
Study: NCT05681585

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation support program
Description: The intervention consists of:~I Implementation strategies:~1.1 Ensuring leadership commitment 1.2 Responsive evaluation 1.3 Whole ward approach 1.4 Train the trainer model 1.5 Sustainability after the study~II Implementation interventions 2.1 Implementation team 2.2 ACP coordinator 2.3 Training and supervision: Kick-off, training of resource persons and health care personnel including practical exercises, network conferences 2.4 Toolkit and shared resources: ACP guideline, teaching material, information leaflets, documentation templates etc. 2.5 Structured fidelity measurements of the implementation level of a) the implementation interventions and b) the clinical intervention, with tailored feedback and supervision~III Clinical intervention: Advance Care Planning 3.1 Routine information and invitation to Advance Care Planning to all eligible patients 3.2 Written information to patients and relatives 3.3 Documentation and collaboration with other health care levels
Study: NCT05552573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low-dose LYB001
Description: This vaccine is prepared through gene recombination and 3 doses of low-dose(30µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low-dose LYB001
Description: This vaccine is prepared through gene recombination and 3 doses of low-dose(30µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (CHO Cell)
Description: This vaccine is Positive-controlled vaccine and 3 doses (0.5ml) at the schedule of 0, 28, 56 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (CHO Cell)
Description: This vaccine is Positive-controlled vaccine and 3 doses (0.5ml) at the schedule of 0, 28, 56 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (CHO Cell)
Description: This vaccine is Positive-controlled vaccine and 3 doses (0.5ml) at the schedule of 0, 28, 56 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (CHO Cell)
Description: This vaccine is Positive-controlled vaccine and 3 doses (0.5ml) at the schedule of 0, 28, 56 days.
Study: NCT05840718

Intervention type: DRUG
Intervention: Thiamin
Description: Patients in thiamine group received two daily dosis of 200 mg of thiamin diluted in 50 ml of 5% dextrose during 7 days
Study: NCT05635071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 100 MG [Ofev]
Description: Nintedanib 100mg bid \*15 days orally after hysteroscopic surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 MG [Ofev]
Description: Nintedanib 150mg bid \*15 days orally after hysteroscopic surgery
Study: NCT04906460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-N531
Description: WVE-N531 is an antisense oligonucleotide (ASO)
Study: NCT05769998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment-based treatment
Description: The ACT-based group intervention includes four 1-hour group sessions over two weeks. The treatment manual was developed by the authors of this study following the ACT framework and adapting materials and resources from ACT-based treatments developed for other settings. The focus of the intervention is to provide patients with pain education specific for patients who underwent TKA and to promote psychological flexibility. Each session employs experiential exercises, including mindfulness meditation, and metaphors addressing the core components of ACT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Standard pharmacotherapy and physical exercise plan provided to all the patients in the rehabilitation unit.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Standard pharmacotherapy and physical exercise plan provided to all the patients in the rehabilitation unit.
Study: NCT05700318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neurostimulator
Description: The ShiraTronics Migraine Therapy System
Study: NCT05552573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high-dose LYB001
Description: This vaccine is prepared through gene recombination and 3 doses of high-dose(60µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high-dose LYB001
Description: This vaccine is prepared through gene recombination and 3 doses of high-dose(60µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
Study: NCT06443242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Dose Laser Acupuncture (LLA)
Description: The intervention utilizes the xS-998D06 semiconductor laser acupoint therapeutic device specifically designed for targeted acupoint therapy. This device is critical in delivering precise low-dose laser therapy at a controlled wavelength and power. The laser treatment is directed towards enhancing neurological function and potentially alleviating symptoms of insomnia and depression by stimulating specific acupoints associated with mental health and sleep.
Study: NCT05361785

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT
Description: FMT from healthy donor or placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FMT
Description: FMT from healthy donor or placebo
Study: NCT05378373

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Garmin, Pattern Health App
Description: Wearable sensors will deliver individualized feedback to participants according to their assigned intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Garmin, Pattern Health App
Description: Wearable sensors will deliver individualized feedback to participants according to their assigned intervention
Study: NCT05593471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity exercises
Description: resistance training progressively increasing according to specific criteria (10 repetitions maximum). for the major muscles of the body

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low intensity aerobic exercises
Description: low-intensity exercises performed using arm or leg ergometer machines
Study: NCT06305104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml EEC
Description: 0.1ml, one time, containing high dose 5μg/ml of active ingredients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 unit（U） EC
Description: 0.1 ml , one time, containing 5U of active ingredients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 unit（U） EC
Description: 0.1 ml , one time, containing 5U of active ingredients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 unit（U） EC
Description: 0.1 ml , one time, containing 5U of active ingredients
Study: NCT05007782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denikitug
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denikitug
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denikitug
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denikitug
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denikitug
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denikitug
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered Intravenously
Study: NCT06507254

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol Supplement
Description: Dietary supplement taken twice daily for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: Dietary supplement taken twice daily for 12 months.
Study: NCT06149403

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Experimental: OTL-203
Description: Experimental: OTL-203: Autologous CD34+ enriched cell fraction that contains hematopoietic stem and progenitor cells transduced ex vivo using lentiviral vector encoding the human IDUA gene

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Allo-HSCT
Description: Active Comparator: Allogeneic hematopoietic stem cell transplantation
Study: NCT06475989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT06628609

Intervention type: OTHER
Group type: OTHER
Intervention: Passive recovery
Description: Volunteers laid in supine position resting for 30 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBMT-sMF
Description: PBMT-sMF applied in the lower limbs with different doses per muscle group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave
Description: Shock wave therapy applied in the lower limbs for 30 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic compression
Description: Pneumatic compression applied in the lower limbs for 30 minutes.
Study: NCT05853783

Intervention type: OTHER
Intervention: STRATICYTE™ Test
Description: Assessment for risk of progression to oral cancer

Intervention type: OTHER
Intervention: STRATICYTE™ Test
Description: Assessment for risk of progression to oral cancer
Study: NCT04307849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Health Club
Description: Sexual health/HIV-related evidence-based interventions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Adolescent Health Club
Description: Sexual health/HIV-related evidence-based interventions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list Control
Description: The wait-listed group will begin the intervention after the intervention group
Study: NCT05133726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text4Support
Description: Daily supportive text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text4Support
Description: Daily supportive text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer support
Description: Meeting with peers who have lived experiences with similar diagnoses but are in recovery
Study: NCT06534541

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attentional bias to food cues
Description: Measurement of the amount of attention given to food cues

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attentional bias to food cues
Description: Measurement of the amount of attention given to food cues
Study: NCT04674826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab administered as 1 × X mL with Device A
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab administered as 1 × X mL with Device A
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
Study: NCT06443242

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Acupuncture (SLA)
Description: Sham laser acupuncture serves as a control to assess the placebo effect of the laser treatment. It involves the same procedure as LLA but uses a non-emitting laser probe. This intervention is designed to mimic the LLA setup without delivering actual laser therapy, allowing for an evaluation of the psychological and physiological effects of the placebo compared to the active laser treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard Medication Management (Control Group)
Description: This intervention involves the continued use of standard pharmacological treatment with SSRIs for managing symptoms of depression. It serves as a control to evaluate the effects of laser acupuncture against conventional medical treatment without the introduction of additional therapeutic modalities. Participants' adherence to their prescribed medication regimen is monitored and documented, ensuring an accurate comparison of treatment effects across groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medication Management (Control Group)
Description: This intervention involves the continued use of standard pharmacological treatment with SSRIs for managing symptoms of depression. It serves as a control to evaluate the effects of laser acupuncture against conventional medical treatment without the introduction of additional therapeutic modalities. Participants' adherence to their prescribed medication regimen is monitored and documented, ensuring an accurate comparison of treatment effects across groups.
Study: NCT05284422

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Peripheral venous catheter insertion
Description: Insertion of a short catheter in a peripheral vein with the help of visualization palpation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided insertion of a peripheral venous catheter
Description: Insertion of a short catheter in a peripheral vein with the help of an ultrasound device
Study: NCT06443242

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard Medication Management (Control Group)
Description: This intervention involves the continued use of standard pharmacological treatment with SSRIs for managing symptoms of depression. It serves as a control to evaluate the effects of laser acupuncture against conventional medical treatment without the introduction of additional therapeutic modalities. Participants' adherence to their prescribed medication regimen is monitored and documented, ensuring an accurate comparison of treatment effects across groups.
Study: NCT04674826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tralokinumab administered as 2 × Y mL with Device B
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
Study: NCT05533437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry needling
Description: the dry needle inserted to area of pain
Study: NCT06534034

Intervention type: PROCEDURE
Intervention: Dental implant placement
Description: Dental implant placement on edentulous jaw.
Study: NCT05533437

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio taping
Description: kinesio taping
Study: NCT05392257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab + zanubrutinib + lenalidomide
Description: Rituximab at 375mg / m2, Day 0; Zanubrutinib 160mg bid continuously oral; Lenalidomide 25mg qd oral on days 1-21; 28 days as a course of treatment
Study: NCT03845751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIFU hemi-ablation combined with ADT.
Description: Hemi-ablation of the cancer-harbouring prostatic lobe will be carried out using HIFU energy. Short-term 3-month ADT will be administered concomitantly. Short-term ADT is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone \[LHRH\] agonist). The ADT protocol starts within 1 month prior to the scheduled HIFU session
Study: NCT05306431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide
Description: Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant
Study: NCT06475989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabrafenib
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05306431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hypochlorite
Description: A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter
Study: NCT05078242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EaseVRx
Description: Participants will experience 7 sessions of the EaseVRx device for chronic pain.
Study: NCT05923528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL
Description: IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated eye mask
Description: Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow®
Description: LipiFlow® can control the variables of temperature, pressure, and MG expression technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyePeace®
Description: The silicone-made flexible hand-held gadget applies regulated, vertical pressure to the closed eyelids.
Study: NCT06475989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trametinib
Description: Given PO